JANX
Price
$16.66
Change
-$0.40 (-2.34%)
Updated
Oct 23 closing price
Capitalization
1.02B
11 days until earnings call
Intraday BUY SELL Signals
URGN
Price
$34.49
Change
-$0.66 (-1.88%)
Updated
Oct 23 closing price
Capitalization
1.69B
11 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

JANX vs URGN

JANX vs URGN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
JANX vs. URGN commentary
Oct 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JANX is a Hold and URGN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for JANX with price predictions
Oct 23, 2026

JANX in downward trend: price may drop because broke its higher Bollinger Band on October 07, 2026

JANX broke above its upper Bollinger Band on October 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 43 similar instances where the stock broke above the upper band. In 39 of the 43 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on JANX as a result. In 78 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The Moving Average Convergence Divergence Histogram (MACD) for JANX turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

JANX moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for JANX crossed bearishly below the 50-day moving average on October 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JANX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for JANX entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where JANX advanced for three days, in 225 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.098) is normal, around the industry mean (3.035). P/E Ratio (-10.159) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (42.194) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. JANX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. JANX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for URGN with price predictions
Oct 23, 2026

URGN in downward trend: price dove below 50-day moving average on September 18, 2026

URGN moved below its 50-day moving average on September 18, 2026 date and that indicates a change from an upward trend to a downward trend. In 34 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on URGN as a result. In 69 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for URGN turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 34 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for URGN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for URGN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where URGN advanced for three days, in 214 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

URGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-12.734) is normal, around the industry mean (3.035). P/E Ratio (-17.508) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (11.403) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. URGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 49 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
URGN: Fundamental Ratings
URGN
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
PROFIT vs RISK RATING
1..100
49
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
23
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
JANXURGN
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 7 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 12 days ago
89%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
Aroon
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
85%
COMPARISON
Comparison
Oct 25, 2026
Stock price -- (JANX: $16.66 vs. URGN: $34.49)
Brand notoriety: JANX and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JANX: 35% vs. URGN: 89%
Market capitalization -- JANX: $1.02B vs. URGN: $1.69B
JANX [@Biotechnology] is valued at $1.02B. URGN’s [@Biotechnology] market capitalization is $1.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JANX’s FA Score shows that 1 FA rating(s) are green while URGN’s FA Score has 2 green FA rating(s).

  • JANX’s FA Score: 1 green, 4 red.
  • URGN’s FA Score: 2 green, 3 red.
According to our system of comparison, URGN is a better buy in the long-term than JANX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JANX’s TA Score shows that 2 TA indicator(s) are bullish while URGN’s TA Score has 4 bullish TA indicator(s).

  • JANX’s TA Score: 2 bullish, 7 bearish.
  • URGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, URGN is a better buy in the short-term than JANX.

Price Growth

JANX (@Biotechnology) experienced а +0.91% price change this week, while URGN (@Biotechnology) price change was -0.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.

Reported Earning Dates

JANX is expected to report earnings on Nov 05, 2026.

URGN is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
JANX
Daily Signal:
Gain/Loss:
URGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BP51.321.27
+2.54%
BP plc
PD17.490.26
+1.51%
PagerDuty
TEAD0.83N/A
N/A
Teads Holding Co
UCFI5.51N/A
N/A
CN Healthy Food Tech Group Corp.
OR32.85-0.48
-1.44%
OR Royalties Inc.

JANX and

Correlation & Price change

A.I.dvisor indicates that over the last year, JANX has been loosely correlated with VIR. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if JANX jumps, then VIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JANX
1D Price
Change %
JANX100%
-2.34%
VIR - JANX
38%
Loosely correlated
+1.34%
ORMP - JANX
36%
Loosely correlated
+0.24%
VTGN - JANX
36%
Loosely correlated
-3.90%
URGN - JANX
36%
Loosely correlated
-1.88%
ELTX - JANX
34%
Loosely correlated
-2.06%
More